Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmnioCyte
- Development stage
- Unknown
- Lead developer
- Predictive Biotech
- Administration
- Topical
01
Overview
AmnioCyte is an amniotic membrane-derived human cell, tissue, and cellular and tissue-based product developed by Predictive Biotech for wound care and tissue repair applications. Rather than acting through a single defined molecular target like a conventional pharmaceutical, it is intended to provide a biologic tissue matrix and regenerative microenvironment that may support healing, tissue coverage, and repair in damaged or nonhealing tissue. It is best characterized as a placental tissue allograft product regulated within the HCT/P framework, not as a traditional small-molecule or biologic drug approved through the standard drug approval pathway.
- Brand names
- AmnioCyte
- Other names
- Q4242Q-4242Q 4242
Beyond the preview
Go deeper on AmnioCyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AmnioCyte.